Cellectricon Launches Grant to Fund Electroporation-based Research
News Jul 10, 2013
As a provider of advanced cell-based screening technologies and services, Cellectricon is inviting researchers to apply for the recently launched Cellaxess Project Grant. The Grant is open to any scientist or research group wanting to capitalize on the advanced electromanipulation capabilities of the Cellaxess® platform for the cellular delivery of non-genetic material, particularly small molecules and peptides. Winners will be selected from two categories, basic and applied cell-based research, and will receive the Cellaxess ACE platform, along with all consumables and reagents, for a fully supported project. Interested groups should submit a research proposal by Wednesday 31st July, explaining how they intend to use the Cellaxess technology in their research project, using the application form available on Cellectricon’s website.
The Cellaxess electroporation system, which can be used for the in-situ transfection of any adherent cell-type, ensures minimal cell processing for perfectly retained cell function and morphology. As such, the platform is ideal for the delivery of non-genetic material, including antibodies, peptides and other small molecules, to challenging cells such as primary and IPS-derived neuronal cell types. Cellectricon welcomes proposals that exploit these unique capabilities of the Cellaxess system and, via the Cellaxess Project Grant, is keen to support and develop the proprietary work of research groups worldwide. Helping to expand the scope of such research, the Grant provides a unique opportunity for scientists to access cutting-edge technologies and gain first-hand advice from Cellectricon’s expert team.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE